EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Demystifying Clone‐Censor‐Weighting to Study Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data

Michael Webster-Clark, Yi Li, Sophie Dell'Aniello, Robert W Platt iD

Pharmacoepidemiology and Drug Safety · 2025-10 · 34 (10)

DOI: 10.1002/pds.70223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 21.09.2025. Verfasst von Michael Webster-Clark und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Medicare, Myocardial Infarction, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clone‐censor‐weighting (CCW) can compare treatment regimens that are initially indistinguishable (such as starting treatment within specific time windows) without using landmarks or creating immortal time. The causal contrasts estimated in these cases and the analyses themselves can become quite complex; however.

Objective

Provide a tutorial on CCW for comparing initiation windows and illustrate the causal contrasts underlying such comparisons.

Methods

We identified patients with myocardial infarctions without past aspirin or clopidogrel use in Medicare's synthetic public data files. We assigned “clones” to three regimens: (1) initiation within 30 days; (2) initiation within 90 days; or 3) initiation from 30 to 90 days. Clones were censored when deviating from their assigned regimen by failing to initiate treatment in time or by initiating treatment too early. We addressed informative censoring using inverse probability of censoring weights (IPCW), calculated weighted 180‐day risks of re‐hospitalization or death using Kaplan–Meier methods, and visualized the portion of the population exposed during the first 90 days to compare exposure distributions underlying regimens.

Results

We identified 1589 patients experiencing myocardial infarction with no past medication use. 15% initiated within 30 days and 26% initiated between 30 and 90 days. After IPCW, the 180‐day outcome risk was 40.2% in the 30‐day regimen, 35.7% in the 90‐day regimen, and 35.2% in the 30‐to‐90 day regimen.

Conclusions

Though CCW can be complex to implement and the effects it estimates can vary substantially across study populations that initiate treatments at different times, it is a useful tool for contrasting initiation windows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicareMyocardial InfarctionPlatelet Aggregation InhibitorsHumansUnited StatesAgedFemaleMaleClopidogrelTime FactorsAspirinAged, 80 and overKaplan-Meier EstimateDatabases, FactualTiclopidine

Stichwörter der Autor:innen

clone‐censor‐weightingselection biastarget trial emulationtreatment timingtreatment windows

Substanzen

ClopidogrelAspirinPlatelet Aggregation InhibitorsTiclopidine

Autor:innen und Institutionen

  • Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Medicine, McGill University, Montreal, Quebec, Canada.
  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
  • Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.

ORCID-Profile: Robert W Platt

Zitieren

APA

Webster-Clark, M., Li, Y., Dell'Aniello, S., & Platt, R. W. (2025). Demystifying Clone‐Censor‐Weighting to Study Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data. Pharmacoepidemiology and Drug Safety, 34(10). https://doi.org/10.1002/pds.70223

Vancouver

Webster-Clark M, Li Y, Dell'Aniello S, Platt RW. Demystifying Clone‐Censor‐Weighting to Study Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data. Pharmacoepidemiology and Drug Safety. 2025;34(10). doi:10.1002/pds.70223

BibTeX
@article{WebsterClark2025,
  author = {Webster-Clark, Michael and Li, Yi and Dell'Aniello, Sophie and Platt, Robert W},
  title = {Demystifying Clone‐Censor‐Weighting to Study Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  volume = {34},
  number = {10},
  doi = {10.1002/pds.70223}
}
Kostenlos starten →